Hong Kong · Delayed Price · Currency is HKD Everest Medicines Earnings Call Transcripts
Fiscal Year 2026
-
The company is driving dual-engine growth through in-house R&D and in-licensing, with strong commercial execution in China. Nefecon leads sales growth, while new deals and innovative platforms in mRNA and BTK inhibitors support long-term expansion.
Fiscal Year 2025
-
Strong revenue growth driven by Nefecon and expanding antibacterial portfolio, with supply constraints resolved and robust sales guidance for 2025–2026. VELSIPITY and SIBO advance toward regulatory milestones, while mRNA and CAR T platforms progress in clinical development.
-
Significant progress was reported on a proprietary mRNA platform, with the first patient dosed in a personalized cancer vaccine trial and IND submissions for an off-the-shelf TAA vaccine. The pipeline, including an in vivo CAR-T program, is advancing toward key 2024 milestones.
Fiscal Year 2024
-
Revenue surged 461% year-over-year to RMB 706.7 million, driven by Nefecon and XERAVA launches, with gross margin at 83% and non-IFRS net loss narrowing by 25%. Nefecon’s NRDL inclusion and strong pipeline progress position the company for continued growth.
-
EVER001, a novel reversible covalent BTK inhibitor, showed strong efficacy and safety in a phase I-B/II-A trial for primary membranous nephropathy, achieving high rates of immunological and clinical remission with favorable tolerability. Plans are underway for global phase II/III studies and broader renal indications.
-
Revenue surged 158% in H1 2024, driven by XERAVA and NEFECON launches, with gross margin at 83% and non-IFRS loss narrowing by 35%. The company is on track for RMB 700 million full-year revenue, advancing mRNA and renal pipelines, and maintaining a strong cash position.
-
Focused on renal and infectious diseases, leveraging in-licensing and internal R&D, with Nefecon’s launch targeting a large, underserved patient base. Commercial execution is strong in both renal and anti-infective portfolios, while mRNA innovation advances toward clinical milestones.